- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06602284
A Full Face Study to Evaluate the Efficacy of Dermapen 4™ Microneedling Device in Addition with MG-CLR Serum for Acne Treatment Over 12 Weeks.
September 16, 2024 updated by: Equipmed USA LLC
A Full Face, Baseline Controlled Study to Evaluate the Efficacy of Dermapen 4™ Microneedling Device in Conjunction with MG-CLR Serum for Acne Treatment Over 12 Weeks.
This study is conducted to check how well the Dermapen 4™ microneedling device works with MG-CLR serum for treating acne over 12 weeks.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
10
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Stene Marshal
- Phone Number: (949) 798 6207
- Email: stene@dermapenworld.com
Study Contact Backup
- Name: Aahan Sachdev
- Phone Number: 9880755883
- Email: aahan.sachdev@msclinical.com
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
- Skin Wellness Dermatology
-
Contact:
- Jordan Rubin
- Phone Number: 205.678.7518
- Email: jrubin@skinwellness.com
-
Contact:
- COREY LOUIS HARTMAN
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Female subjects aged between 18-45 years (both ages inclusive)
- Fitzpatrick skin phototype I to VI.
- Subjects having IGA score of 2 and 3.
- Subjects who have not received any kind of treatment for acne 1 month before the start of the study.
- Subject free of excessive hair, cuts, abrasions, fissures, wounds, lacerations, or any other skin conditions on the face.
- Subjects who agree not to use any other product/treatment/home remedy/ except the provided products on their face during the study period
Exclusion Criteria:
- Subjects with known skin condition that may impact the assessment.
- Subjects with active Herpes labialis infection.
- Subjects known to have bleeding and clotting disorders (self-declared).
- Subjects known to have connective tissue disorders.
- Subjects with any other signs of significant local irritation or skin disease.
- Subjects currently taking any medication, which the investigator believes may influence the interpretation of the data.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: A single arm, full face clinical study.
Dermapen 4 in conjunction with MG-CLR serum
|
Dermapen 4™ conjunction with MG-CLR
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acne severity
Time Frame: 13 weeks
|
Change in acne severity using the modified GAGS scale at all time points when compared to baseline.
|
13 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
October 1, 2024
Primary Completion (Estimated)
March 1, 2025
Study Completion (Estimated)
March 1, 2025
Study Registration Dates
First Submitted
September 16, 2024
First Submitted That Met QC Criteria
September 16, 2024
First Posted (Estimated)
September 19, 2024
Study Record Updates
Last Update Posted (Estimated)
September 19, 2024
Last Update Submitted That Met QC Criteria
September 16, 2024
Last Verified
September 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SKIN/EMAC/2024-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Sharing Time Frame
protocol will be available soon after approval
IPD Sharing Access Criteria
Sponsor and CRO/site personals
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.